BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LEO Pharma readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies LEO Pharma's drugs run\, from Cli
 nicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03886246-42@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Spevigo (spesolimab): Phase 2 readout est. (NCT03886246)
DESCRIPTION:Spevigo (spesolimab)\, phase 2\, Psoriasis.\nStudy: Effisayil
 ™ ON: A Study to Test Long-term Treatment With Spesolimab in People With
  Generalized Pustular Psoriasis Who Took Part in a Previous Study\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03886246
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624670-42@assetmemo.bio
DTSTAMP:20261121T005832Z
DTSTART;VALUE=DATE:20271112
DTEND;VALUE=DATE:20271113
SUMMARY:Spevigo (spesolimab): Phase 3 readout est. (NCT06624670)
DESCRIPTION:Spevigo (spesolimab)\, phase 3.\nStudy: A Study to Test Whether
  Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
 \nEstimated primary completion: 12 November 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06624670
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
